listeo-data-scraper domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/healingmaps.imarkdev.com/wp-includes/functions.php on line 6170
The Oregon Health Authority wanted $20,000 annual licenses. Community surveys suggested enough licensees would quit that the state would collect less than it does today.
Read More
A proposed rule would place five tryptamines into Schedule I. It is the second attempt at the same action, and comments close October 23.
Read More
From FDA's October 5 psychedelics docket to the DEA telehealth expiration and Medicare's 2027 in-person rule, six dates every ketamine clinic should plan around.
Read More
ARPA-H's ASCENT-IBO program funds Phase 1 and 2 ibogaine trials for opioid use disorder, with patient safety up front. Solution summaries are due October 15.
Read More
Virginia passed a trigger law for FDA-approved psilocybin, and both Compass Pathways and Journey Clinical plan to launch at existing Spravato sites.
Read More
FDA heard four hours of testimony on psychedelic approval and asked no questions. The real contest was over label language, which decides who can deliver these drugs.
Read More
A Center for Health Care Strategies report examines how psychedelic-assisted therapy could reach Medicaid. Some states already cover off-label IV ketamine.
Read More
The WSJ reported that a SpaceX director gave $25 million to recapitalize the company behind MDMA-assisted therapy. That explains a strategy that looked strange.
Read More
The American Legion adopted a resolution backing psychedelic therapy for veterans. It endorses S.4220, which would build a VA office and ban step therapy.
Read More
FDA cited Alar Pharmaceuticals over claims for an investigational ketamine product. The flagged phrases show up in a lot of clinic marketing.
Read More